'Stunning' 4% yearly rise in R&D share has emerging biopharma dominating pipeline

Emerging biopharmas have gradually taken over the R&D pipeline, producing two-thirds of all new drugs in 2022, a finding one financial biotech player called "stunning."

"Emerging biopharma has been rising at roughly 4% a year for each of the last five years," Tim Opler, Ph.D., managing director for life sciences investment bank Torreya, said during a March 29 presentation of IQVIA’s report on global R&D trends. Opler, citing the IQVIA data, dubbed the stat an "absolutely stunning finding."